Samsung's next foldables look crazy thin in this new leak
Hadlee Simons / Android Authority
TL;DR New 'official' images of the Galaxy Z Fold 7 and Galaxy Z Flip 7 have leaked.
The images show both foldables in two different colorways.
These colorways are said to be called Blue Shadow and Jet Black.
Samsung is gearing up to launch the next generation of its foldable phones. As we inch closer to the eventual announcement, predictably, leaks have been ramping up. Previously, we've seen CAD renders of both the Galaxy Z Fold 7 and Galaxy Z Flip 7. Now, a new leak claims to give us a look at 'official' renders of both handsets.
Courtesy of Android Headlines, we have a new collection of renders for the Galaxy Z Fold 7 and Flip 7 to check out. These 'official' renders present both foldables in two colorways, which are reportedly called Blue Shadow and Jet Black. More colorways are expected to be available, but these are the only two included in this report.
According to earlier leaks, Samsung has made both foldables fairly thinner than previous iterations. The Fold 7, in particular, is rumored to be about 4.54mm thin when unfolded, which would be only slightly thicker than the OPPO Find N5 (4.21mm). In the images above, we can see the Flip 7 and the Fold 7 compared to their predecessors. While the Flip has never been overly thick, it's clear Samsung has found a way to cut off some of the fat. However, the difference in size is even more noticeable between the Fold 7 and Fold 6.
Both devices are also expected to get larger cover displays. For the Flip 7, Samsung is ditching the manila folder-like design and is opting to use the entire cover. Meanwhile, the cover display on the Fold 7 is expected to grow from 6.3 inches to 6.5 inches. This will also result in a bigger inner screen, which is said to be 8.2 inches.
Rumors are pointing to June 9 as the date for Samsung's next Unpacked event. If true, that means we'll only have to wait a few more weeks for the launch. In addition to these foldables, it's expected that Samsung's next smartwatches will appear at the show. We could possibly even get a teaser for Project Moohan.
Got a tip? Talk to us! Email our staff at
Email our staff at news@androidauthority.com . You can stay anonymous or get credit for the info, it's your choice.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Android Authority
43 minutes ago
- Android Authority
Samsung Galaxy S25 FE leak points to thinner bezels
TL;DR A new leak may give us our first look at the Galaxy S25 FE. The device is said to feature a 6.7-inch Super AMOLED display with a 120Hz refresh rate. Samsung may have upgraded the front camera to 12MP. In January, Samsung launched the Galaxy S25, S25 Plus, and S25 Ultra. The company then followed that up with the launch of the Galaxy S25 Edge in May. Samsung could finish up the S25 series in the next few months by launching a Fan Edition, and we may have just gotten our first look at it. In collaboration with tipster OnLeaks, SamMobile has shared a few CAD renders of what's believed to be the Galaxy S25 FE. According to the outlet, the FE will come with a 6.7-inch Super AMOLED display with a 120Hz refresh rate. That display may offer a peak brightness of 2,600 nits, but that number hasn't been confirmed. We could also see the front camera upgraded from 10MP to 12MP. Additionally, the report mentions that we can expect the dimensions to be 161.4 x 76.6 x 7.4mm. While there are no details about the price, the outlet speculates that the price could go up by $50. For reference, the Galaxy S24 FE launched with a price tag of $650. It's also unclear what chip will be sitting inside, but potential options could be an Exynos 2400 or a MediaTek Dimensity 9400. These renders also seem to suggest that the bezels will be thinner than last year. It's believed that Samsung could launch the Galaxy S25 FE in late Q3 or early Q4 of this year. When the handset arrives, it should be running on One UI 8 out of the box. Got a tip? Talk to us! Email our staff at Email our staff at news@ . You can stay anonymous or get credit for the info, it's your choice.
Yahoo
an hour ago
- Yahoo
QIAGEN's New QIAcuity dPCR IVD Pact With GENCURIX May Boost Its Stock
QIAGEN N.V. QGEN has announced a new partnership with South Korea-based GENCURIX, Inc. to develop oncology assays for use on the QIAcuityDx digital PCR (dPCR) platform. The molecular diagnostics company is the first development partner under QIAGEN's QIAcuityDx Partnering Program, designed to enable the generation of a broad menu of in-vitro diagnostics (IVD) assays on the QIAcuityDx Four platform, increasing access to digital PCR diagnostics. The latest development is expected to significantly boost the company's Precision Diagnostics business under the Diagnostic Solutions product group. Shares of QIAGEN stayed flat in the aftermarket following the announcement of the news yesterday. The collaboration with GENCURIX represents the first step in building a robust and innovative assay ecosystem for the QIAcuityDx platform, backed by QIAGEN's distribution capabilities and technical support. Accordingly, market sentiment surrounding QGEN stock should stay positive, driven by the news. QIAGEN has a market capitalization of $10.35 billion. The company has an earnings yield of 5%, well above the industry's -29.3% yield. In the trailing four quarters, it delivered an average earnings surprise of 4.9%. The QIAcuityDx Partnering Program aims to support third-party assay development on QIAcuityDx. A member of the QIAcuity family of dPCR systems, the platform had more than 2,700 cumulative placements since its launch by the end of 2024. These menu initiatives for clinical applications will leverage this installed base and build on the 2024 milestone of launching more than 130 new assays for QIAcuity for research applications, complemented by the extensive menu of custom assays available on QIAGEN's GeneGlobe platform. Image Source: Zacks Investment Research Under this first partnership, GENCURIX will apply its proven expertise in complex, multiplex IVD assay development to create oncology tests. GENCURIX will begin developing multiple oncology assays and pursue IVD regulatory approvals. As the legal manufacturer of the assays, GENCURIX will be fully responsible for obtaining and maintaining all necessary regulatory approvals and certifications. Upon approval, the assays will be marketed through QIAGEN's global commercial infrastructure as part of the QIAcuityDx Partnering Program, ensuring streamlined access for laboratories worldwide. Per a research report, the global IVD market was valued at $108.30 billion in 2024 and is expected to grow at a compound annual rate of 5.6% through 2030. The growing demand for accurate, rapid and personalized diagnostic solutions globally is fueling the market's growth. The expansion is also supported by the integration of digital health, AI and data analytics into diagnostic platforms, helping enhance test accuracy and clinical decision-making. Last week, the company announced a new global collaboration with Incyte to develop a novel diagnostic panel to support the latter's extensive portfolio of investigational therapies for patients with myeloproliferative neoplasms (MPNs), a group of rare blood cancers. Under the agreement terms, QIAGEN will develop a multimodal panel using next-generation sequencing (NGS) technology for detecting clinically relevant gene alterations in hematological malignancies. Over the past year, QGEN shares have risen 8.1% against the industry's 16.1% decline. QIAGEN currently carries a Zacks Rank #2 (Buy). Some other top-ranked stocks in the broader medical space are Phibro Animal Health PAHC, Hims & Hers Health HIMS and Cencora COR. While Phibro Animal Health sports a Zacks Rank #1 (Strong Buy) at present, Hims & Hers Health and Cencora each carry a Zacks Rank #2. You can see the complete list of today's Zacks #1 Rank stocks here. Estimates for Phibro Animal Health's fiscal 2025 earnings per share have jumped 5.2% to $2.04 in the past 30 days. Shares of the company have rallied 35.1% in the past year compared with the industry's 7.7% growth. Its earnings yield of 8.5% compares comfortably with the industry's 0.5% yield. PAHC's earnings surpassed estimates in each of the trailing four quarters, the average surprise being 30.6%. Hims & Hers Health shares have surged 172.8% in the past year. Estimates for the company's 2025 earnings per share have jumped 2.8% to 73 cents in the past 30 days. HIMS' earnings beat estimates twice in the trailing four quarters, matched in one and missed on another occasion, the average surprise being 19.6%. In the last reported quarter, it posted an earnings surprise of 66.7%. Estimates for Cencora's fiscal 2025 earnings per share have increased 0.4% to $15.75 in the past 30 days. Shares of the company have jumped 25.9% in the past year against the industry's 16.2% fall. COR's earnings surpassed estimates in each of the trailing four quarters, the average surprise being 6%. In the last reported quarter, it delivered an earnings surprise of 8.3%. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report QIAGEN N.V. (QGEN) : Free Stock Analysis Report Cencora, Inc. (COR) : Free Stock Analysis Report Phibro Animal Health Corporation (PAHC) : Free Stock Analysis Report Hims & Hers Health, Inc. (HIMS) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
Scientists unite with AI to record dreams
Dreaming is a fascinating state where creativity runs wild, crafting vivid, cinematic scenes that can feel as real as everyday life—until you wake up and they vanish into memory or disappear from your recollection altogether. But what if there were a way to capture, record, and playback your dreams in the real world? At ATR Computational Neuroscience Laboratories in Kyoto, Japan, a group of scientists unveiled a complex system that uses functional magnetic resonance imaging (fMRI) and AI to 'record' people's dreams and play them back in a rough, estimated form. The experiment focused on closely observing the brain's electrical and blood flow activity in a select group of volunteers as they slept. To achieve this, researchers combined an electroencephalogram (EEG) with an fMRI machine, allowing participants to spend several nights sleeping while their brain activity was recorded. During the REM stage of sleep—when brain activity surges and dreams unfold—participants were gently awakened and asked to recount their dreams. This process was repeated hundreds of times, creating a rich database that linked distinct brain-scan patterns to specific dream imagery. Using this carefully constructed database, scientists employed deep learning algorithms to attempt to reconstruct visual content while the volunteers slept. During the tests, the system achieved approximately 60% accuracy, rising to over 70% on more specific categories like people or objects. Professor Yukiyasu Kamitani stated, 'We were able to reveal dream content from brain activity during sleep, which was consistent with the subjects' verbal reports.' The idea of watching your dreams play out like a vintage film is undeniably captivating, but the implications for neuroscience and mental health are equally remarkable. In the future, this innovative approach could be harnessed to explore emotional and cognitive patterns in various mental health conditions, providing a non-verbal and impartial glimpse into the subconscious. As the technology advances, it holds the potential to deepen our understanding of both human consciousness and the subconscious mind. However, while the technology is still in its early stages, the results it produces are often blurry and indistinct. Key elements such as colour, motion, narrative structure, and emotion remain largely elusive for now. Currently, dreams can only be captured in retrospect, after the subject has awakened, rather than in real-time. Dr. Mark Stokes points out that "all of this would have to be done within individual subjects," meaning that a universal classifier capable of interpreting anyone's dreams is not feasible. In essence, a dream-reading machine is not a one-size-fits-all solution. Nonetheless, this experiment represents a significant leap forward in the field of "oneirography," which involves the recording and documentation of dreams. As advancements in fMRI, EEG, and AI continue, the boundary between our internal mental experiences and external observation is starting to blur. "Scientists unite with AI to record dreams" was originally created and published by Verdict, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.
